inobrodib
cellcentric
['inobrodib', 'multiple myeloma', 'pioneer']
#aacr23 orlando. continues to advance its pioneering oral small molecule drug, inobrodib. inhibits p300/cbp, impacts irf4 &amp; myc. most advanced efficacy data in relapsed refractory multiple myeloma. 
Biotech CEO, Dir, Chair; CellCentric, Cyted, F2G, VaxEquity. Morningside Ventures. Prev. JIC, BBSRC, BIA.